INTREXON CORP

Insider

First SEC filing: Jan. 11, 2016 · Latest: Jan. 11, 2016

On this page

Biography Career background and public profile, where available.
Insider at Companies where this person is a reporting insider.
Insider transactions Every share this person bought or sold, from Form 4 filings.
Derivatives Options and other derivative holdings reported by this person.

Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.

## History

In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

Insider at

PGEN

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 1 non-open-market transaction below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Jan. 7, 2016	PGEN	A	275,000	—	—	275,000 Direct	—	Acquired	(price as of 2026-08-19)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Jan. 7, 2016	PGEN	Option to Purchase Common Stock (Right to Buy)	Common Stock (275,000)	$27.14	Jan. 7, 2026	275,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).